Search

Objective: Rheumatoid Arthritis (RA) is a chronic destructive inflammatory disorder. This study is aimed to investigate the effects of balneotherapy and aquatherapy in the treatment of RA patients. Materials and Methods: A total of 59 patients who fulfilled the American College of Rheumatology diagnostic criteria for RA were included this study. Patients were randomly assigned into three groups. Group 1 (n=20) received balneotherapy, group 2 (n=20) received an aquatic exercise program and group 3 (n=19) was accepted as control group. These programs were applied five times a week, over three weeks (15 sessions). Patients were evaluated for clinical and laboratory parameters. Clinical parameters included pain,duration of morning stiffness, number of swollen and tender joints, disease activity score (DAS28), Modified health assessment questionnaire (mHAQ), physician's and patient's global assessment and hand grip strength. Laboratory evaluation included erythrocyte sedimentation rate(ESR) and C-reactive protein (CRP). The assessment parameters were measured before, at the end of and after 3 months of the therapy. Results: The mean age of the patients was 54±10.7 (25-75) years and the mean disease duration was 122.3±98.1 (1-424) months. In aquatic exercise group we observed an improvement in DAS28 scores (p<0.001), in the number of tender joints (p<0.005), in VAS scores (p<0.005), mHAQ (p<0.05), physician's and patient's global assessments (p<0.05). Also there was a statistically significant decrease in ESR results in aquatherapy group compared to other groups (p<0.05). However no statistically significant difference was obtained between three groups (p>0.05). Conclusion: This study shows that aquatic exercise program is beneficial in the management of DAS28, pain, HAQ parameters and should be taken in to consideration in planning exercise therapy for RA patients. [ABSTRACT FROM AUTHOR]

Aim: Minerals and trace elements affect bone formation and resorption through direct or indirect effects on bone cells or bone mineral. Strontium has several effects on bone cells and anabolic activity. Materials and Methods: The effects of strontium ranelate on pain and bone mineral density were assessed in an open, noncontrolled trial conducted in postmenopausal women. Oral strontium ranelate was given at a daily dose of 2 g for six months in 31 patients. All women received calcium and vitamin D supplements. Measurements of bone mineral density were performed before treatment and at the sixth month. Blood biochemistry analysis was performed at the beginning and at the 6th month. Results: Pain (visual analog scala) score was 6.12±1.05 at baseline and 4.25±0.92 at sixth month of treatment. Pain decreased significantly at 6th month (p<0.05). New fractures did not occur during the study. Strontium renalate treatment increased bone mineral density at 6th month at the total lumbar spine and the femoral total region. The changes were found to be statistically significant (p<0.05). There were no serious adverse events. None of the patients discontinued treatment due to adverse effects. The blood biochemistry was normal at baseline and end of the trial. Global efficacy was good in 64.5% of patients at sixth month. Tolerability was excellent during the study (80.6%). Conclusion: Treatment of postmenopausal osteoporosis with strontium ranelate can decrease pain, and increase bone mineral density beginning at six months following treatment. The results have to be considered as preliminary, the study was planned for a longer duration on a greater number of patients. (Turkish Journal of Osteoporosis 2012;18: 53-7) [ABSTRACT FROM AUTHOR]